Comparative Evaluation of 18F-Flurpiridaz and 82Rb-Chloride PET Myocardial Perfusion Imaging: The FLARE (Flurpiridaz vs. Rubidium Evaluation) Trial
University of California, Los Angeles
Summary
This study seeks to evaluate if the diagnostic performance of 18F-flurpiridaz positron emission tomography (PET) myocardial perfusion imaging (MPI), given the radiotracer's properties, is non-inferior to the currently most widely utilized PET MPI radiopharmaceutical, 82Rb-chloride.
Description
* Patients will undergo a clinically indicated rest/stress 82Rb-chloride positron emission tomography (PET) myocardial perfusion imaging (MPI) and will return to the nuclear cardiology laboratory within 1-30 days to undergo a 18F-flurpiridaz PET MPI and coronary CT angiogram. A rest 18F-flurpiridaz PET MPI will be acquired first, followed by a stress 18F-flurpiridaz PET MPI. The waiting period between the rest and stress 18F-flurpiridaz PET acquisitions will be ≥ 30 minutes. The rest dose will be 2.5-3.0 mCi, and the pharmacological stress dose will be 6.0-6.5 mCi. All PET MPI studies will be…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Patient scheduled for a clinically indicated 82Rb-chloride PET MPI * Age ≥ 18 years * Ability to provide consent Exclusion Criteria: * Previous participation in a 18F-flurpiridaz clinical trial * Prior myocardial infarction * Prior coronary revascularization (percutaneous coronary intervention and/or coronary artery bypass grafting) * History of orthotopic heart transplantation * Inability to control heart rate \< 65 bpm * Frequent ventricular or atrial ectopy leading to irregular cardiac rhythm * Creatinine ≥ 1.4 mg/dL * Pregnant or breast-feeding status
Location
- West Los Angeles Veterans Affairs Medical CenterLos Angeles, California